Effects of pyrrophenone, an inhibitor of group IVA phospholipase A2, on eicosanoid and PAF biosynthesis in human neutrophils
Open Access
- 1 October 2006
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (4) , 385-392
Abstract
Background and Purpose: The biosynthesis of leukotrienes (LT) and platelet‐activating factor (PAF) involves the release of their respective precursors, arachidonic acid (AA) and lyso‐PAF by the group IVA PLA2 (cPLA2α). This paper aims at characterizing the inhibitory properties of the cPLA2α inhibitor pyrrophenone on eicosanoids and PAF in human neutrophils (PMN).Experimental Approach: Freshly isolated human PMN were activated with physiological and pharmacological agents (fMLP, PAF, exogenous AA, A23187 and thapsigargin) in presence and absence of the cPLA2α inhibitor pyrrophenone and biosynthesis of LT, PAF, and PGE2 was measured.Key Results: Pyrrophenone potently inhibited LT, PGE2 and PAF biosynthesis in PMN with IC50s in the range of 1–20 nM. These inhibitory effects of pyrrophenone were specific (the consequence of substrate deprivation), as shown by the reversal of inhibition by exogenous AA and lyso‐PAF. Comparative assessment of pyrrophenone, methyl‐arachidonoyl‐fluoro‐phosphonate (MAFP) and arachidonoyl‐trifluoromethylketone (AACOCF3) demonstrated that pyrrophenone was more specific and 100‐fold more potent than MAFP and AACOCF3 for the inhibition of LT biosynthesis in A23187‐activated PMN. The inhibitory effect of pyrrophenone on LT biosynthesis was reversible as LT biosynthesis was recovered when pyrrophenone‐treated PMN were washed with autologous plasma. No alteration of phospholipase D (PLD) activity in fMLP‐activated PMN was observed with up to 10 μM pyrrophenone, suggesting that the cPLA2α inhibitor does not directly inhibit PLD.Conclusions and Implications: Pyrrophenone is a more potent and specific cPLA2α inhibitor than MAFP and AACOCF3 and represents an excellent pharmacological tool to investigate the biosynthesis and the biological roles of eicosanoids and PAF.British Journal of Pharmacology (2006) 149, 385–392. doi:10.1038/sj.bjp.0706879Keywords
This publication has 35 references indexed in Scilit:
- Inhibition of platelet-activating factor biosynthesis by adenosine and histamine in human neutrophils: involvement of cPLA2α and reversal by lyso-PAFJournal of Leukocyte Biology, 2006
- Inhibition of Platelet-Activating Factor (PAF) Acetylhydrolase by Methyl Arachidonyl Fluorophosphonate Potentiates PAF Synthesis in Thrombin-Stimulated Human Coronary Artery Endothelial CellsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Arachidonic acid activates phospholipase D in human neutrophils; essential role of endogenous leukotriene B4 and inhibition by adenosine A2A receptor engagementJournal of Leukocyte Biology, 2003
- Characterization of a novel inhibitor of cytosolic phospholipase A2α, pyrrophenoneBiochemical Journal, 2002
- A pyrrolidine-based specific inhibitor of cytosolic phospholipase A2α blocks arachidonic acid release in a variety of mammalian cellsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2001
- Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2Bioorganic & Medicinal Chemistry Letters, 2001
- Irreversible inhibition of Ca2+-independent phospholipase A2 by methyl arachidonyl fluorophosphonateBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating proteinEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Lipopolysaccharides prime whole human blood and isolated neutrophils for the increased synthesis of 5-lipoxygenase products by enhancing arachidonic acid availability: involvement of the CD14 antigen.Journal of Experimental Medicine, 1993
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959